How Are Authorized Representative Responsibilities Defined for Overseas Registration of POCT Products?

The division of responsibilities for an authorized representative (AR) in overseas registration of POCT products directly determines registration success and compliance costs. First, determine how the target country regulates POCT products: if they are medical devices (e.g., under EU IVDR, U.S. FDA classification, or Southeast Asian medical device directives), the registration pathway depends on risk class. The AR typically handles submission of technical documents, communication with regulatory authorities, post-market surveillance, and adverse event reporting. The manufacturer must provide complete technical files, including performance evaluation, risk management, clinical evaluation (self-testing POCT requires clinical trials), and quality management system certificates (ISO 13485 or MDSAP). Common risks include: an AR lacking POCT product experience (e.g., rapid testing, non-professional users) leading to mismatched registration dossiers; local agent qualifications not meeting requirements; and improper reuse of documents for multi-country registrations (e.g., failing to localize CE technical files according to GHWP requirements). It is recommended that companies select an AR with POCT background early, and clearly define responsibility boundaries, certificate control, change, and renewal obligations in the contract. Preparing English technical files in advance and adapting them to target country requirements can significantly reduce repeat corrections. For Middle East and Latin American markets, POCT is often classified as 'rapid test reagents,' and the AR must assist with local clinical trial exclusions or performance verification waivers. For post-market maintenance, contracts should set adverse event response timelines and service quality indicators to avoid product import suspension due to AR delays. In summary, correctly defining AR responsibilities is fundamental to efficiently entering overseas markets with POCT products.

Key Summary

When registering POCT products overseas, the division of AR responsibilities directly determines registration success and compliance costs. First, clarify the target country's regulatory definition of POCT products: if they are medical devices (e.g., EU IVDR, U.S. FDA classification, Southeast Asian medical device directives), the registration pathway depends on risk class. The AR usually handles technical document submission, communication with regulators, post-market surveillance, and adverse event reporting. Companies must provide complete technical files, including performance evaluation, risk management, clinical evaluation (self-testing POCT requires clinical trials), and QMS certificates (ISO 13485 or MDSAP). Common risks include: an AR without POCT product experience (e.g., rapid testing, non-professional users) leading to mismatched files; unqualified local agents; and improper document reuse in multi-country registration (e.g., not localizing CE files per GHWP requirements). We recommend early selection of an AR with POCT background and clear contract terms covering responsibility boundaries, certificate control, changes, and renewal obligations. Preparing English technical files in advance and adapting them to target country requirements can greatly reduce corrective submissions. For Middle East and Latin America, POCT is often considered a 'rapid test reagent'; the AR must help apply for local clinical trial exemptions or performance verification waivers. For post-market maintenance, contracts should define adverse event response times and service quality metrics to prevent import suspensions caused by AR delays. In short, correct AR responsibility division is the cornerstone for POCT products to enter overseas markets efficiently. Companies should integrate AR management into their overall registration strategy.

Applicable Scenarios and Core Issues

POCT products, characterized by rapid, convenient, and non-professional operation, often face special requirements in overseas registration. The authorized representative (AR) is the legal entity responsible for coordinating with local authorities, submitting registration files, and handling post-market surveillance. Applicable scenarios include: direct export by the brand owner, OEM/ODM contract manufacturing with label branding, and joint registration (multiple companies sharing one AR). Core issues are: who bears primary registration responsibility? Who prepares technical documentation? How is post-market surveillance implemented? Unclear division of responsibilities can lead to registration delays, corrections, or even product recalls. Companies must define the AR's specific duties according to the target country's regulations.

For example, EU regulations require non-European manufacturers to designate an EU authorized representative (EC REP) responsible for serious incident reporting and on-site inspection coordination. In the U.S., although the FDA does not mandate an authorized representative, many importers act as 'U.S. agents' with similar responsibilities. Southeast Asian, Middle Eastern, and other GHWP member countries generally require local registration agents to hold government qualifications.

Registration Decision Logic

Step 1: Determine Regulatory Scope

Decide whether the product falls within the target country's medical device regulatory scope. For example, POCT blood glucose test strips in the U.S. may be subject to FDA 510(k) or CLIA waiver; under EU IVDR they are typically classified as Class B or C.

Step 2: Determine Risk Class

Self-testing POCT products are usually Class D (highest risk under IVDR) or Class III (FDA Class III), requiring more stringent clinical evidence.

Step 3: Select the Registration Pathway

The U.S. may use 510(k) or PMA; the EU depends on classification for self-declaration or notified body review; many Southeast Asian countries use a simplified GHWP-based pathway.

Step 4: Assess Reuse of Existing Data

NMPA registration data on performance, risk management, and QMS (ISO 13485) are often directly usable for overseas registration, but clinical evaluation, labeling, and local agent information must be localized per target country requirements.

Step 5: Confirm AR Qualifications

Different countries impose requirements on legal personality, registered address, and professional staff for ARs. For example, Saudi Arabia requires the AR to be a locally licensed importer recognized by SFDA.

Step 6: Clarify Certificate Control and Renewal Obligations

The AR agreement should state whether the registration certificate is held by the AR or returned to the company, and specify timelines and responsibilities for renewal and changes.

Documentation and Evidence

Companies need to prepare the following evidence to prove that the AR is capable of fulfilling its responsibilities:

• A formal appointment agreement between the manufacturer and the AR, clearly listing responsibilities (e.g., document submission, communication, post-market reporting).
• The AR's business license or regulatory filing proof.
• Technical file summaries, including performance evaluation reports, risk management reports (ISO 14971), and clinical evaluation plans or reports (including sample size and statistical methods).
• Quality management system certificates (e.g., ISO 13485 or MDSAP).
• POCT product labels and instructions for use, translated into the target country's official language and adapted to local culture (e.g., pictorial instructions, warning statements).
• A post-market surveillance (PMS) plan, including adverse event reporting procedures and periodic safety reports.
• For multi-country registration, note that technical file formats vary (e.g., U.S. eCopy, EU IVDR Annex II, Southeast Asian Common Submission Dossier Template). It is advisable to base files on English technical documentation and adapt to each country's requirements.

Common Errors

• AR qualifications do not meet target country requirements: for example, selecting a non-local company as an agent leads to registration rejection.
• Inaccurate technical document translation: the simple operation and rapid results of POCT products are not reflected in the labeling, raising regulatory concerns.
• Neglecting post-market surveillance obligations: the AR fails to report adverse events in a timely manner, resulting in import suspension or fines.
• Unclear certificate ownership: when the registration certificate is held by the AR, the company cannot control changes or renewals, creating a passive situation.
• Contract does not define change procedures: if product specifications, labels, or manufacturing sites change, the AR does not update registration information in time.
• Improper reuse of multi-country documents: submitting CE technical files to Southeast Asian countries without adding local clinical evaluations or performance verifications as required.

Enterprise Preparation Checklist

• Confirm the target country's medical device definition and POCT product classification; obtain the latest regulatory requirements.
• Choose an authorized representative with POCT product experience and local regulatory qualifications; conduct a background check.
• Sign a detailed AR agreement defining responsibilities, certificate control, change procedures, renewal obligations, and response times.
• Prepare English technical files: performance data, risk management, quality management system, and clinical evaluation (if applicable).
• Translate labels and instructions for use into the target language, ensuring compliance with local regulations (e.g., CE marking, UDI, warnings).
• Submit the registration application; the AR assists with local notarization, translation, and submission.
• Establish a post-market surveillance system, including adverse event collection procedures and periodic safety report templates.
• Maintain certificates: track validity, start renewal at least six months before expiry, and ensure AR cooperation for updates.

AIMEILI Perspective

From a regulatory consulting standpoint, the division of AR responsibilities in overseas registration of POCT products is one of the most misjudged areas. Many companies believe having an overseas distributor or local company is enough, but overlook the AR's independent legal liability. During early project planning, companies should complete a target-country regulatory applicability analysis, determine product classification and registration pathway, and then rigorously select an AR. Prioritize authorized representatives who have successfully registered similar POCT products and request success cases and regulatory communication records.

For data reuse, performance validation data, risk management documents, and ISO 13485/MDSAP certificates are generally globally reusable. Clinical evaluation requires special attention: EU IVDR requires clinical performance studies for Class C and above POCT products, while Southeast Asia and the Middle East may accept comparative testing or exemption justifications. Labels and instructions for use must be in the local language and adapted to local conventions for figures and warnings. In the AR agreement, strive for the registration certificate to be directly held by the company or jointly managed, otherwise a change of AR can invalidate the registration.

For multi-country registration (e.g., GHWP member states), it is advisable to choose a country with stable regulations that accepts CE or FDA documentation (such as Singapore or Saudi Arabia) as an anchor. Complete registration there first, then expand to other countries. This reduces duplicate document preparation and correction risks, and lowers total costs. Additionally, contracts should set specific response times for the AR's adverse event reporting (e.g., notify the company within 24 hours, submit regulatory reports within 7 days), and include confidentiality clauses to prevent disclosure of trade secrets. In conclusion, the AR is a critical node in the overseas registration chain; companies must manage it from a strategic compliance standpoint rather than passively delegating it.

Common Follow-up Questions

Can an authorized representative simultaneously represent multiple companies for similar POCT products?

Usually yes, but there is a risk of conflict of interest. For example, if the same AR represents two competing POCT products, it might leak technical details or delay submissions. Companies should check the AR's client list before signing and sign confidentiality agreements. In some countries (e.g., Indonesia), regulations require the AR to file separately for each product, which does not prevent simultaneous representation of multiple products. However, if products are highly similar, the AR must demonstrate the ability to handle each registration case independently.

Does POCT product registration in Southeast Asia require local clinical trials?

It depends on classification and evidence. Most Southeast Asian countries (e.g., Thailand, Vietnam, the Philippines) follow GHWP guidelines and accept CE or FDA clinical data, but may require additional local population validation or reagent stability tests. For example, Indonesia requires local clinical studies for self-testing HIV POCT. If the product already has EU IVDR or FDA clinical evidence, companies may apply for an exemption but must provide scientific justification. It is advisable to consult a local authorized representative or regulatory agent in advance.

What clauses must be included in an authorized representative agreement?

At minimum, the agreement should include: rights and obligations of both parties; ownership and usage rights of the registration certificate; notification obligations for changes (product, manufacturing, label, etc.); post-market surveillance responsibilities (adverse event reporting, assistance with inspections); renewal and registration transfer procedures; fee settlement; confidentiality clauses; breach and compensation clauses; dispute resolution mechanism (arbitration recommended); and transitional arrangements upon termination (e.g., transferring registration to a new AR).

Implementation Recommendations

In actual projects, companies should break this issue into five tasks: regulatory judgment, document preparation, evidence reuse, localization, and post-market maintenance. This should not be left to one department to compile files at the last minute. This approach helps identify data gaps earlier and enables sales, R&D, quality, and regulatory teams to reach a consistent understanding of target-country requirements.

If the company plans to enter multiple markets simultaneously, it is best to first develop a unified core technical file, then supplement authorization, labeling, language, forms, and local agent information for each country. The efficiency of multi-country registration often depends on whether the upfront document framework is unified, not on the submission speed of any single country.

First confirm whether the product falls under the target country's medical device regulatory scope. Then confirm the risk class, registration pathway, and applicant. Check that technical documents, quality systems, and clinical evidence support each other. Clarify the roles of the local agent, authorized representative, and certificate control. Establish a mechanism for post-market changes, renewals, and vigilance events.

Further Reading

• Previous: How to choose a local agent for POCT product overseas registration?
• Next: Can test reports be reused for medical device registration in Australia?
• Recommended: How to choose a local agent for IVD product overseas registration?
• Recommended: How are authorized representative responsibilities divided for IVD product overseas registration?
• Recommended: Why do IVD product overseas registration timelines get extended?
• Recommended: What are common reasons for supplemental information requests in IVD overseas registration?
• Recommended: How to conduct post-market surveillance for IVD products overseas?
• Recommended: When must a registration change be filed for IVD products overseas?
• Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundary

Author: AIMEILI Regulatory Editorial Team
Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory authorities, international organizations, standards bodies, and publicly available regulatory documents; industry media and project experience are used only as supplementary judgment.

Applicability Boundary: This article is for preliminary understanding, document preparation, and project planning. It does not replace the official requirements of target-country regulatory authorities, testing conclusions, or legal advice.